SGS Life Science to Expand Shanghai Facility
News Aug 04, 2014
The company will offer new services from the facility, including a new biotechnology laboratory for cytotoxicity testing, cell-based assays, plus endotoxin and ELISA testing. The current 1500 square meter facility provides services for method development and validation, testing of raw materials, APIs and finished products, as well as testing of Traditional Chinese Medicines.
The expansion program, which is due to commence in August 2014, will also see the introduction of packaging testing, including extractables and leachables, while an inductively coupled plasma mass spectrometer, for USP <233> Elemental Impurities, will also be located within the laboratory. Other new capabilities at the Shanghai site will include a dissolution lab for generic drug stability studies, a mycoplasma lab focused on the biological market, and a highly active compound (HAC) testing laboratory to meet growing market demand. In addition to new office space, a drug compatibility study lab, designed to meet regulatory requirements, will also be introduced.
“The investment in the Shanghai facility, and the increased and enhanced service offerings that will result, are essential to our continued expansion in China,” commented Andy Yi, General Manager, SGS Life Science Services, Shanghai. He added, “Much of the work that we undertake is on behalf of major multinational customers who demand that their drug and medical device products are subject to the same level of compliance and scrutiny that they would be if they had been manufactured in the West. This expansion will further serve the quality requirements of those customers.”
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE